Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders. Primarily affecting the pulmonary interstitium, these diseases are characterized by inflammation, fibrosis, or a combination of both. This article provides a comprehensive overview of ILDs, their pathophysiology, diagnosis, and management strategies.
ILDs are typically the result of an exaggerated or misdirected repair response to lung injury. Inflammatory cells infiltrate the interstitium, leading to fibroblast proliferation, collagen deposition, and eventual architectural distortion. This process results in impaired gas exchange, restrictive lung physiology, and respiratory failure if unchecked.
Diagnosis of ILDs requires a thorough clinical evaluation, including a detailed history and physical examination. High-resolution computed tomography (HRCT) is the imaging modality of choice, revealing characteristic patterns such as ground-glass opacities, reticulations, and honeycombing. Pulmonary function tests show a restrictive pattern with reduced diffusion capacity. Lung biopsy, though not always necessary, can provide definitive diagnosis in certain cases.
Management of ILDs is complex and multifaceted. It primarily focuses on halting disease progression and improving quality of life. Treatment options include corticosteroids, immunosuppressive agents, and antifibrotic drugs. Lung transplantation may be considered in advanced cases. Multidisciplinary team involvement is crucial for optimal patient care.
Interstitial lung diseases present a significant challenge due to their diversity and complex pathophysiology. Early recognition, accurate diagnosis, and appropriate management can significantly improve patient outcomes. As our understanding of these diseases continues to evolve, so too will our therapeutic strategies, underscoring the importance of ongoing research in this field.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation